Allogene Therapeutics, Inc. ALLO
We are a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. We are developing a pipeline of "off-the-shelf" T cell product candidates that are designed to target and kill cancer cells in patients or eliminate pathogenic autoreactive cells in patients with autoimmune disorders. Our engineered T cells are allogeneic, meaning they are derived from healthy donors for intended use in any patient, rather than from an individual patient for that patient's use, as in the case of autologous T cells. We believe this key difference will enable us to deliver readily available treatments faster, more reliably, at greater scale, and to more patients.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $22.0K | $95.0K | $156.0K | $114.1M | $0 | $0 | — | — |
| R&D | $150.2M | $192.3M | $242.9M | $256.4M | $220.2M | $193.0M | $144.5M | $151.9M | — |
| SG&A | $56.8M | $65.2M | $71.7M | $79.3M | $74.1M | $65.3M | $57.5M | $41.0M | — |
| Total operating expenses | $209.3M | $273.2M | $327.8M | $335.7M | $294.3M | $258.2M | $202.0M | $192.8M | — |
| Operating income | -$209.3M | -$273.2M | -$327.7M | -$335.5M | -$180.2M | -$258.2M | -$202.0M | -$192.8M | — |
| Interest expense | $1.1M | $181.0K | $0 | — | — | $0 | $0 | $3.4M | — |
| Pre-tax income | -$190.9M | -$257.1M | -$327.3M | -$340.4M | -$257.0M | -$250.2M | -$184.9M | -$211.6M | — |
| Income tax | $0 | $443.0K | $0 | $0 | $0 | $0 | $331.0K | $117.0K | — |
| Net income | -$190.9M | -$257.6M | -$327.3M | -$340.4M | -$182.1M | -$316.4M | -$184.6M | -$211.5M | — |
| EPS, basic | -0.87 | -1.32 | -2.09 | -2.38 | -1.34 | -2.63 | -1.83 | — | — |
| EPS, diluted | -0.87 | -1.32 | -2.09 | -2.38 | -1.34 | -2.63 | -1.83 | -7.31 | — |
| Shares, diluted (wtd. avg.) | 220.6M | 194.8M | 156.9M | 143.1M | 135.8M | 120.4M | 101.1M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $51.7M | $75.2M | $93.4M | $72.2M | $173.3M | $192.8M | $179.4M | $93.7M | $0 |
| Short-term investments | $198.5M | $217.3M | $365.5M | $394.5M | $284.0M | $644.6M | $355.4M | $367.0M | — |
| Total current assets | $257.7M | $303.4M | $459.1M | $513.0M | $471.3M | $845.1M | $544.6M | $468.0M | — |
| Property, plant and equipment | $72.8M | $86.1M | $99.5M | $117.2M | $123.0M | $118.8M | $56.4M | $8.6M | — |
| Other intangibles | — | — | — | — | — | $0 | $151.0K | $754.0K | — |
| Total assets | $415.9M | $548.7M | $642.8M | $955.6M | $1.05B | $1.23B | $717.8M | $773.9M | — |
| Accounts payable | $4.3M | $5.4M | $5.9M | $9.7M | $10.3M | $10.4M | $9.2M | $12.3M | — |
| Total current liabilities | $32.5M | $35.5M | $37.1M | $44.2M | $47.9M | $94.3M | $33.1M | $29.5M | $2.0K |
| Total liabilities | $123.4M | $126.5M | $130.6M | $149.1M | $125.6M | $148.2M | $88.8M | $70.7M | $2.0K |
| Retained earnings | -$2.01B | -$1.82B | -$1.56B | -$1.05B | -$894.6M | -$712.5M | -$396.1M | -$211.5M | -$23.0K |
| Total equity | $292.5M | $422.2M | $512.2M | $666.9M | $925.2M | $1.01B | $629.0M | $703.2M | -$2.0K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$149.2M | -$200.3M | -$237.7M | -$220.5M | -$184.8M | -$115.1M | -$137.3M | -$44.7M | — |
| Depreciation and amortisation | $12.4M | $13.6M | $14.2M | $14.3M | $10.5M | $7.4M | $4.6M | $1.0M | — |
| Stock-based compensation | $37.6M | $51.7M | $66.0M | $83.6M | $80.8M | $65.3M | $46.1M | $18.6M | — |
| Capital expenditure | $386.0K | $694.0K | $1.5M | $5.2M | $21.4M | $66.0M | $50.8M | $3.2M | — |
| Investing cash flow | $95.6M | $75.7M | $163.3M | $106.2M | $163.7M | -$505.1M | $164.1M | -$632.8M | — |
| Financing cash flow | $30.2M | $116.7M | $95.7M | $3.0M | $12.0M | $633.6M | $59.0M | $771.2M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-028948.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $0 | $114.1M | $156.0K | $95.0K | $22.0K | $0 |
| Gross profit | — | — | — | — | — | — | — | — | — |
| Net income | — | -$211.5M | -$184.6M | -$316.4M | -$182.1M | -$340.4M | -$327.3M | -$257.6M | -$190.9M |
Recent filings and events
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Officer or director change Item 5.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
- Results announced Item 2.02
- Other event Item 8.01
- Other event Item 8.01
- Other event Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |